Publications by authors named "Pin Zhang"
Background: Distinguishing bariatric surgical effects on reversing nonalcoholic fatty liver disease (NAFLD) remain unclear. To assess discrepancies in histological response and changes in magnetic resonance imaging-proton density fat fraction (MRI-PDFF) after bariatric surgery.
Methods: This prospective multicenter cohort included 138 NAFLD patients who underwent bariatric surgery and were followed up for 1 year.
Processing curved surface with a high-speed triple galvanometer laser 3D scanning system.
Opt Express
March 2025
High-speed laser processing of curved surfaces is limited by laser three-dimensional (3D) scanning equipment. It is difficult to balance efficiency and uniformity during processing. In this paper, a self-developed high-speed triple galvanometer laser 3D scanning system (TGLSS) was used.
View Article and Find Full Text PDFAims: This study compared pathologic complete response (pCR) rates to neoadjuvant chemotherapy (NAC) in HER2-negative early breast cancer patients with versus without homologous recombination repair (HRR) mutation, focusing on BRCA1/2.
Methods: This retrospective cohort study included HER-2-negative breast cancer patients who completed HRR genetic testing and received NAC. The primary endpoint was the pCR rate among HRR mutation carriers and noncarriers.
Microstructure and Property Evolution of Pure Copper Under Asynchronous Rolling.
Materials (Basel)
June 2025
This study investigates the impact of asynchronous rolling on the microstructure, tensile properties, and electrical conductivity of pure copper. Pure copper sheets were subjected to asynchronous rolling with asynchronous ratios of 1.0 and 1.
View Article and Find Full Text PDFBackground: A growing number of antibody‒drug conjugates (ADCs) have been approved for breast cancer treatment. However, the proper sequential strategies of ADCs remain uncertain. Our study aimed to explore the ideal ADC sequential treatment strategies in human epidermal growth factor receptor 2 (HER2)-expressing metastatic breast cancer (MBC).
View Article and Find Full Text PDFBackground: Pathological complete response (pCR) has been proven to be related to prognosis. pCR can be further classified as pCR of the breast (bpCR), pCR of axillary lymph nodes (apCR) or pCR of both tumors. The aim of this study was to elucidate the outcomes and clinicopathological characteristics associated with different patterns of pCR.
View Article and Find Full Text PDFEmerging science supports the role of lipid metabolism disorders in the occurrence and development of chronic diseases. Dietary intervention has been shown to be an effective strategy for regulating lipid metabolism. Recent studies showed that perilla is rich in various effective ingredients, including fatty acids, flavonoids, and phenolic acids.
View Article and Find Full Text PDFPurpose: This study aims to explore the role of the non-luminal disease score (NOLUS) for everolimus in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC).
Methods: NOLUS has previously been established as an algorithm: NOLUS (0-100) = - 0.45 × ER(%) - 0.
Objectives: The purpose of this study was to investigate the quality of life (QoL) of older Chinese patients with breast cancer and to explore further the associations of functions, symptoms, financial burdens and comorbidities with global health/quality of life (gQoL).
Design: This was a cross-sectional study carried out following the Strengthening the Reporting of Observational Studies in Epidemiology checklist.
Setting: This study was conducted in two hospitals in Beijing from October 2021 to November 2022.
Five-year outcomes of metabolic surgery in Chinese subjects with type 2 diabetes.
Chin Med J (Engl)
February 2025
circ_0075048 silencing regulates LCP1 to improve IL-1β-induced chondrocyte injury by binding with miR-663b.
J Orthop Surg Res
January 2025
Background: Osteoarthritis (OA) is a common type of degenerative arthropathy. Previous studies have demonstrated that circular RNAs (circRNAs) are involved in the progression of OA. This study aimed to investigate the role and associated mechanism of circ_0075048 in OA.
View Article and Find Full Text PDFThe Influence of the COVID-19 Pandemic on Infection in Children, Henan, China.
Indian J Microbiol
December 2024
Article Synopsis
- - The study aimed to assess the prevalence of frailty and its effects on quality of life in older breast cancer patients in China, a topic not well-explored previously.
- - Conducted as a multi-centre registry study, data was gathered from three hospitals between October 2021 and July 2023, focusing on patients over 65 who completed various assessment scales for frailty, mental health, and quality of life.
- - Among the 946 participants, 8.8% were identified as frail, with higher rates seen in those aged 75 or older and those with advanced cancer or mental health issues; significant predictors of frailty included older age, advanced tumors, anxiety, and depression.
With the emergence of the precision medicine era, targeting specific proteins has emerged as a pivotal breakthrough in tumor diagnosis and treatment. Apurinic/apyrimidinic Endonuclease 1 (APE1) is a multifunctional protein that plays a crucial role in DNA repair and cellular redox regulation. This article comprehensively explores the fundamental mechanisms of APE1 as a multifunctional enzyme in biology, with particular emphasis on its potential significance in disease diagnosis and strategies for tumor treatment.
View Article and Find Full Text PDFArticle Synopsis
- A clinical trial compared the effectiveness and safety of gemcitabine plus capecitabine (GX) versus gemcitabine plus carboplatin (GC) in treating advanced triple-negative breast cancer (TNBC) patients.
- The results showed that while median progression-free survival (PFS) was similar, the GC regimen was more effective, particularly in patients with high tumor-infiltrating lymphocytes (TILs).
- The GX regimen is still considered for patients who might struggle with the side effects associated with the GC treatment, particularly hematological toxicity.
Background: Everolimus is beneficial for patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). However, some patients developed drug resistance and the well-established predictor for everolimus efficacy was limited.
Objectives: The study was designed to evaluate the efficacy of everolimus in different treatment lines and identify several clinicopathological markers to estimate everolimus efficacy in patients with HR+/HER2- ABC.
Background: The selection of appropriate chemotherapy backbone agents in combination with neoadjuvant immunotherapy for triple-negative breast cancer (TNBC) remains unclear. Herein, we aimed to evaluate the efficacy and safety of anthracycline-free and anthracycline-containing regimens coupled with neoadjuvant immunotherapy.
Method: This retrospective study included 87 patients with TBNC who received neoadjuvant immunotherapy combined with various chemotherapy regimens at three research centers from November 2020 to November 2023.
Article Synopsis
- Slow transit constipation (STC) is becoming more common, and Shouhui Tongbian capsule (SHTB), a traditional Chinese medicine, shows promise in treating it, although its mechanisms are not fully understood.
- Researchers used various methods, like mass spectrometry and microbiome analysis, to study how SHTB works in repairing gut health and affecting lipid metabolism in STC.
- Results showed SHTB improved intestinal barrier function, decreased inflammation, and normalized gut bacteria, highlighting its role in reducing lipid buildup and restoring microbial balance as key treatment mechanisms for STC.*
Article Synopsis
- A study explored the effectiveness of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and everolimus (EVE) for treating hormone receptor-positive, HER2-negative metastatic breast cancer in 146 patients in China.
- Patients were divided into two groups based on the order of treatment: those who received CDK4/6i first (Group A) and those who received it after EVE (Group B).
- The study found no significant differences in progression-free survival or overall survival between the two groups, suggesting that either treatment sequence could be a viable option for patients.
Article Synopsis
- The study recognizes that de novo metastatic breast cancer (dnMBC) is a diverse disease, highlighting that current staging systems do not adequately classify patients within the M1 or stage IV category, prompting a need for refinement.
- Researchers analyzed data from nearly 12,000 dnMBC patients to create a more precise prognostic staging system, which was validated using additional patient cohorts, focusing on factors like tumor stage, histological grade, and the number of metastatic sites.
- The proposed stratification divides the M1 stage into three groups based on metastatic involvement, revealing that individuals with more severe stages (particularly M1c) have poorer overall survival and may not benefit as much from surgery compared to those in less severe categories (like
Article Synopsis
- CDK4/6 inhibitors in combination with endocrine therapy have become key treatments for hormone receptor-positive advanced breast cancer, and ongoing research explores the benefits of switching to a different CDK4/6 inhibitor after disease progression.
- In a study of 82 patients who switched CDK4/6 inhibitors, the median progression-free survival was 7.6 months, with some patients experiencing up to 10.7 months of survival after switching therapies.
- The study identified lung metastasis and switching to endocrine therapy as factors that could influence treatment outcomes, with hematologic toxicity being the most common severe side effect observed.
Article Synopsis
- The study evaluated the conversion of HER-2 zero or low status in HER-2 negative breast cancer patients following neoadjuvant chemotherapy (NAC) and its impact on prognosis.
- It included 571 patients, revealing a 32.4% change rate in HER-2 status, with hormone receptor-positive patients showing a significant link to HER-2 zero to low conversion.
- Results indicated that HER-2 zero to low conversion led to improved disease-free survival in HER-2 zero patients, especially those who were hormone receptor-positive, suggesting implications for potential anti-HER-2 treatments post-NAC.
Background: Inetetamab is a novel antibody targeting human epidermal growth factor receptor 2 (HER2) developed in China. Due to its optimized antibody-dependent cell-mediated cytotoxicity effect compared with trastuzumab, it has shown good efficacy and safety in the treatment of HER2-positive advanced breast cancer (ABC).
Objectives: This study aimed to investigate the efficacy and safety of inetetamab combination therapy in the treatment of HER2-positive ABC in real-world clinical practice.
Article Synopsis
- HR+/HER2-breast cancer patients can experience long-term survival even without achieving a pathologic complete response (pCR), highlighting a need for better prognostic indicators.
- This study assessed the significance of major pathologic response (MPR) as a predictor of event-free survival (EFS) in patients who underwent neoadjuvant chemotherapy and surgery.
- Results indicated that patients achieving MPR had significantly better EFS compared to those who did not, suggesting MPR could be a more effective prognostic tool than pCR in this patient group.
Background: Dalpiciclib is a novel cyclin-dependent kinase 4/6 inhibitor which showed tolerability and preliminary efficacy as monotherapy for pretreated advanced breast cancer (BC).
Objectives: To further assess dalpiciclib with endocrine therapy (ET) in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative BC.
Design: A multicenter, open-label, phase Ib trial.